Lisdexamfetamine

Because of the gradual release of active dextroamphetamine, lisdexamfetamine tends to produce less peak-related jitteriness and less end-of-dose rebound compared to IR amphetamine formulations. This is a pharmacokinetic advantage, not the absence of side effects. All stimulant class side effects still apply (appetite suppression, insomnia, increased heart rate/blood pressure, headache, irritability/mood changes, growth suppression in children, emotional blunting at excessive doses, rare stimulant-induced psychosis). These are covered in detail on the methylphenidate page.

The 10-14 hour clinical effect can extend stimulant activity into the evening, interfering with sleep onset. Unlike IR formulations where the last dose can be timed to avoid evening effects, lisdexamfetamine's duration is fixed. If insomnia is problematic, the only options are to reduce the dose (which may reduce daytime efficacy) or add a sleep aid (melatonin, clonidine, guanfacine).

Same class effect as all stimulants. May be perceived as less abrupt than with IR formulations because the onset is more gradual. Management strategies are the same as described on the methylphenidate page: substantial breakfast before or with the medication, high-calorie snacks during wear-off, adequate dinner when appetite returns.

Reported more commonly with lisdexamfetamine than with some other stimulant formulations. Related to sympathomimetic effects on salivary glands.

Raynaud-like phenomena (cold, painful, discolored fingers/toes) can occur. Monitor for digital complaints, particularly in cold weather. This applies to all stimulants but is worth emphasizing.

The serotonergic component of dextroamphetamine becomes more relevant at higher doses. While clinically significant serotonin syndrome from standard doses is uncommon, vigilance increases with polypharmacy involving other serotonergic medications.